Huay Cheem Tan
Presidente presso Singapore Heart Foundation
Profilo
Huay Cheem Tan is currently the Chairman of the Singapore Heart Foundation and a Professor at the Yong Loo Lin School of Medicine.
He previously served as an Independent Non-Executive Director at HeMo (China) Bioengineering Co., Ltd.
and held the position of President at the Singapore Cardiac Society from 2003 to 2005 and the Asian Pacific Society of Interventional Cardiology from 2014 to 2019.
Tan received his graduate degree from the National University of Singapore in 1992.
Posizioni attive di Huay Cheem Tan
| Società | Posizione | Inizio |
|---|---|---|
| Yong Loo Lin School of Medicine | Corporate Officer/Principal | - |
| Singapore Heart Foundation | Presidente | - |
Precedenti posizioni note di Huay Cheem Tan
| Società | Posizione | Fine |
|---|---|---|
| Asian Pacific Society of Interventional Cardiology | Presidente | 01/01/2019 |
| Singapore Cardiac Society | Presidente | 01/01/2005 |
HeMo (China) Bioengineering Co., Ltd.
 HeMo (China) Bioengineering Co., Ltd. Information Technology ServicesTechnology Services HeMo Bioengineering Ltd. operates as a medical device company. Its portfolio of neuro-interventional medical devices covers all of the ischemic stroke, hemorrhagic stroke and neuro access fields. The company was founded in June 21, 2017 and is headquartered in Weihai, China. | Direttore/Membro del Consiglio | - |
Formazione di Huay Cheem Tan
| National University of Singapore | Graduate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Aziende private | 4 |
|---|---|
| Singapore Heart Foundation | |
| Singapore Cardiac Society | |
HeMo (China) Bioengineering Co., Ltd.
HeMo (China) Bioengineering Co., Ltd. Information Technology ServicesTechnology Services HeMo Bioengineering Ltd. operates as a medical device company. Its portfolio of neuro-interventional medical devices covers all of the ischemic stroke, hemorrhagic stroke and neuro access fields. The company was founded in June 21, 2017 and is headquartered in Weihai, China. | Technology Services |
| Asian Pacific Society of Interventional Cardiology |
- Borsa valori
- Insiders
- Huay Cheem Tan
